We are live on ! Find out more
BLRX

BioLineRX
BLRX

24 hedge funds and large institutions have $13.9M invested in BioLineRX in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

0% less ownership

Funds ownership: 0.04% → 0.04% (-0%)

15% less capital invested

Capital invested by funds: $16.3M → $13.9M (-$2.42M)

23% less funds holding

Funds holding: 31 → 24 (-7)

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
24
Holders Change
-7
Holders Change %
-22.58%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$179K
2
DG
Delek Group
Israel
+$59.7K
3
NFG
Next Financial Group
Texas
+$12.3K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$10.8K
5
DWM
Doyle Wealth Management
Florida
+$1.12K

Top Sellers

Rank Fund Capital Flow
1
EMG
ETF Managers Group
New Jersey
-$157K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$33K
3
SM
Sabby Management
Florida
-$16K
4
Citadel Advisors
Citadel Advisors
Florida
-$14K
5
UBS Group
UBS Group
Switzerland
-$5K

BLRX Hedge Fund Activity: Q2 2019 in Review

24 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2019, worth a combined $13.9M — down 15% from $16.3M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BLRX and 1 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was Morgan Stanley, adding an estimated $179K. The largest seller was ETF Managers Group, exiting entirely with an estimated $157K sold.

  • 24 institutional investors held BioLineRX (BLRX) as of Q2 2019, down from 31 in Q1 2019.
  • Funds reported $13.9M of BioLineRX stock for Q2 2019, down 15% quarter-over-quarter.
  • 1 fund opened new BioLineRX positions in Q2 2019 and 7 closed out, a net change of -6 holders.
  • The largest BioLineRX buyer in Q2 2019 was Morgan Stanley, an estimated $179K added.
  • The largest BioLineRX seller in Q2 2019 was ETF Managers Group, an estimated $157K sold.

Based on aggregated 13F filings for Q2 2019.